New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
14:53 EDTARRYArray BioPharma to present positive Phase 2 data on ARRY-797
Array BioPharma announced that an abstract discussing the final Phase 2 trial results with ARRY-797 in patients with osteoarthritis pain will be presented at the 2012 American College of Rheumatology Annual Meeting in Washington, D.C. This abstract includes data on ARRY-797's analgesic effect and markers of disease modification. In addition, biomarkers of cartilage (COMP) and bone (CTX I) degradation were assessed. ARRY 797 treatment resulted in statistically significant decreases in COMP and CTX I at week 4 (decreases of 10% and 38% versus placebo, respectively). The decrease in CTX I was sustained and returned to baseline by the follow up visit. The abstract concludes that further evaluation of the potential for disease modifying activity is warranted.
News For ARRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
10:49 EDTARRYArray BioPharma management to meet with Piper Jaffray
Subscribe for More Information
September 29, 2014
08:07 EDTARRYPhase 2 trial of binimetinib in NRAS melanoma shows promising clinical activity
Subscribe for More Information
September 23, 2014
09:54 EDTARRYArray BioPharma management to meet with Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use